Selected research
Market Analysis & Forecast
Global SPECT Radiopharmaceuticals Market Analysis and Forecast 2026-2032
Market perspective
The global SPECT Radiopharmaceuticals market is projected to grow from US$ million in 2026 to US$ million by 2032, at a Compound Annual Growth Rate (CAGR) of % during the forecast period.
The North America market for SPECT Radiopharmaceuticals is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.
Europe market for SPECT Radiopharmaceuticals is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.
Read the full market overview
Asia-Pacific market for SPECT Radiopharmaceuticals is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.
The China market for SPECT Radiopharmaceuticals is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.
The major global companies of SPECT Radiopharmaceuticals include Siemens Healthineers, NorthStar Medical Radioisotopes, Molecular Imaging, Inc., Lantheus Medical Imaging, IBA Molecular Imaging, GE Healthcare, Eczacibasi-Monrol, Curium Pharma and Cardinal Health, etc. In 2025, the world's top three vendors accounted for approximately % of the revenue.
Report Includes
This report presents an overview of global market for SPECT Radiopharmaceuticals, market size. Analyses of the global market trends, with historic market revenue data for 2021 - 2025, estimates for 2026, and projections of CAGR through 2032.
This report researches the key producers of SPECT Radiopharmaceuticals, also provides the revenue of main regions and countries. Of the upcoming market potential for SPECT Radiopharmaceuticals, and key regions or countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.
This report focuses on the SPECT Radiopharmaceuticals revenue, market share and industry ranking of main manufacturers, data from 2021 to 2026. Identification of the major stakeholders in the global SPECT Radiopharmaceuticals market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.
This report analyzes the segments data by Type and by Application, revenue, and growth rate, from 2021 to 2032. Evaluation and forecast the market size for SPECT Radiopharmaceuticals revenue, projected growth trends, production technology, application and end-user industry.
SPECT Radiopharmaceuticals Segment by Company
Siemens Healthineers
NorthStar Medical Radioisotopes
Molecular Imaging, Inc.
Lantheus Medical Imaging
IBA Molecular Imaging
GE Healthcare
Eczacibasi-Monrol
Curium Pharma
Cardinal Health
Bracco Imaging
Bayer (Radiology Division)
Advanced Accelerator Applications
SPECT Radiopharmaceuticals Segment by Type
Indium-111 (In-111) Based Agents
Thallium-201 (Tl-201)
Gallium-67 (Ga-67)
Iodine-123 (I-123) Based Agents
Technetium-99m (Tc-99m) Based Agents
SPECT Radiopharmaceuticals Segment by Application
Cardiac Imaging
Brain Imaging
Thyroid Imaging
Infection and Inflammation Imaging
Cancer Imaging
SPECT Radiopharmaceuticals Segment by Region
North America
United States
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Spain
Netherlands
Switzerland
Sweden
Poland
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America
Brazil
Argentina
Chile
Middle East & Africa
Egypt
South Africa
Israel
Türkiye
GCC Countries
Study Objectives
1. To analyze and research the global status and future forecast, involving growth rate (CAGR), market share, historical and forecast.
2. To present the key players, revenue, market share, and Recent Developments.
3. To split the breakdown data by regions, type, manufacturers, and Application.
4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.
5. To identify significant trends, drivers, influence factors in global and regions.
6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global SPECT Radiopharmaceuticals market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of SPECT Radiopharmaceuticals and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in market size), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market.
5. This report helps stakeholders to gain insights into which regions to target globally.
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of SPECT Radiopharmaceuticals.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Revenue of SPECT Radiopharmaceuticals in global and regional level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 4: Detailed analysis of SPECT Radiopharmaceuticals company competitive landscape, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.
Chapter 5: Provides the analysis of various market segments by type, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 6: Provides the analysis of various market segments by application, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 7: Provides profiles of key companies, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, SPECT Radiopharmaceuticals revenue, gross margin, and recent development, etc.
Chapter 8: North America by type, by application and by country, revenue for each segment.
Chapter 9: Europe by type, by application and by country, revenue for each segment.
Chapter 10: China type, by application, revenue for each segment.
Chapter 11: Asia (excluding China) type, by application and by region, revenue for each segment.
Chapter 12: South America, Middle East and Africa by type, by application and by country, revenue for each segment.
Chapter 13: The main concluding insights of the report.
More report detail
Tables and figures
Scope & coverage.
Types
- Indium-111 (In-111) Based Agents
- Thallium-201 (Tl-201)
- Gallium-67 (Ga-67)
- Iodine-123 (I-123) Based Agents
- Technetium-99m (Tc-99m) Based Agents
Applications
- Cardiac Imaging
- Brain Imaging
- Thyroid Imaging
- Infection and Inflammation Imaging
- Cancer Imaging
Companies covered
- Siemens Healthineers
- NorthStar Medical Radioisotopes
- Molecular Imaging, Inc.
- Lantheus Medical Imaging
- IBA Molecular Imaging
- GE Healthcare
- Eczacibasi-Monrol
- Curium Pharma
- Cardinal Health
- Bracco Imaging
- Bayer (Radiology Division)
- Advanced Accelerator Applications
Inside the report.
1 Market Overview
- 1.1 Product Definition
- 1.2 SPECT Radiopharmaceuticals Market by Type
- 1.2.1 Global SPECT Radiopharmaceuticals Market Size by Type, 2021 VS 2025 VS 2032
- 1.2.2 Indium-111 (In-111) Based Agents
- 1.2.3 Thallium-201 (Tl-201)
- 1.2.4 Gallium-67 (Ga-67)
- 1.2.5 Iodine-123 (I-123) Based Agents
- 1.2.6 Technetium-99m (Tc-99m) Based Agents
- 1.3 SPECT Radiopharmaceuticals Market by Application
- 1.3.1 Global SPECT Radiopharmaceuticals Market Size by Application, 2021 VS 2025 VS 2032
- 1.3.2 Cardiac Imaging
- 1.3.3 Brain Imaging
- 1.3.4 Thyroid Imaging
- 1.3.5 Infection and Inflammation Imaging
- 1.3.6 Cancer Imaging
- 1.4 Assumptions and Limitations
- 1.5 Study Goals and Objectives
2 SPECT Radiopharmaceuticals Market Dynamics
- 2.1 SPECT Radiopharmaceuticals Industry Trends
- 2.2 SPECT Radiopharmaceuticals Industry Drivers
- 2.3 SPECT Radiopharmaceuticals Industry Opportunities and Challenges
- 2.4 SPECT Radiopharmaceuticals Industry Restraints
3 Global Growth Perspective
- 3.1 Global SPECT Radiopharmaceuticals Market Perspective (2021-2032)
- 3.2 Global SPECT Radiopharmaceuticals Growth Trends by Region
- 3.2.1 Global SPECT Radiopharmaceuticals Market Size by Region: 2021 VS 2025 VS 2032
- 3.2.2 Global SPECT Radiopharmaceuticals Market Size by Region (2021-2026)
- 3.2.3 Global SPECT Radiopharmaceuticals Market Size by Region (2027-2032)
4 Competitive Landscape by Players
- 4.1 Global SPECT Radiopharmaceuticals Revenue by Players
- 4.1.1 Global SPECT Radiopharmaceuticals Revenue by Players (2021-2026)
- 4.1.2 Global SPECT Radiopharmaceuticals Revenue Market Share by Players (2021-2026)
- 4.1.3 Global SPECT Radiopharmaceuticals Players Revenue Share Top 10 and Top 5 in 2025
- 4.2 Global SPECT Radiopharmaceuticals Key Players Ranking, 2024 VS 2025 VS 2026
- 4.3 Global SPECT Radiopharmaceuticals Key Players Headquarters & Area Served
- 4.4 Global SPECT Radiopharmaceuticals Players, Product Type & Application
- 4.5 Global SPECT Radiopharmaceuticals Players Establishment Date
- 4.6 Market Competitive Analysis
- 4.6.1 Global SPECT Radiopharmaceuticals Market CR5 and HHI
- 4.6.3 2025 SPECT Radiopharmaceuticals Tier 1, Tier 2, and Tier 3
5 SPECT Radiopharmaceuticals Market Size by Type
- 5.1 Global SPECT Radiopharmaceuticals Revenue by Type (2021 VS 2025 VS 2032)
- 5.2 Global SPECT Radiopharmaceuticals Revenue by Type (2021-2032)
- 5.3 Global SPECT Radiopharmaceuticals Revenue Market Share by Type (2021-2032)
6 SPECT Radiopharmaceuticals Market Size by Application
- 6.1 Global SPECT Radiopharmaceuticals Revenue by Application (2021 VS 2025 VS 2032)
- 6.2 Global SPECT Radiopharmaceuticals Revenue by Application (2021-2032)
- 6.3 Global SPECT Radiopharmaceuticals Revenue Market Share by Application (2021-2032)
7 Company Profiles
- 7.1 Siemens Healthineers
- 7.1.1 Siemens Healthineers Company Information
- 7.1.2 Siemens Healthineers Business Overview
- 7.1.3 Siemens Healthineers SPECT Radiopharmaceuticals Revenue and Gross Margin (2021-2026)
- 7.1.4 Siemens Healthineers SPECT Radiopharmaceuticals Product Portfolio
- 7.1.5 Siemens Healthineers Recent Developments
- 7.2 NorthStar Medical Radioisotopes
- 7.2.1 NorthStar Medical Radioisotopes Company Information
- 7.2.2 NorthStar Medical Radioisotopes Business Overview
- 7.2.3 NorthStar Medical Radioisotopes SPECT Radiopharmaceuticals Revenue and Gross Margin (2021-2026)
- 7.2.4 NorthStar Medical Radioisotopes SPECT Radiopharmaceuticals Product Portfolio
- 7.2.5 NorthStar Medical Radioisotopes Recent Developments
- 7.3 Molecular Imaging, Inc.
- 7.3.1 Molecular Imaging, Inc. Company Information
- 7.3.2 Molecular Imaging, Inc. Business Overview
- 7.3.3 Molecular Imaging, Inc. SPECT Radiopharmaceuticals Revenue and Gross Margin (2021-2026)
- 7.3.4 Molecular Imaging, Inc. SPECT Radiopharmaceuticals Product Portfolio
- 7.3.5 Molecular Imaging, Inc. Recent Developments
- 7.4 Lantheus Medical Imaging
- 7.4.1 Lantheus Medical Imaging Company Information
- 7.4.2 Lantheus Medical Imaging Business Overview
- 7.4.3 Lantheus Medical Imaging SPECT Radiopharmaceuticals Revenue and Gross Margin (2021-2026)
- 7.4.4 Lantheus Medical Imaging SPECT Radiopharmaceuticals Product Portfolio
- 7.4.5 Lantheus Medical Imaging Recent Developments
- 7.5 IBA Molecular Imaging
- 7.5.1 IBA Molecular Imaging Company Information
- 7.5.2 IBA Molecular Imaging Business Overview
- 7.5.3 IBA Molecular Imaging SPECT Radiopharmaceuticals Revenue and Gross Margin (2021-2026)
- 7.5.4 IBA Molecular Imaging SPECT Radiopharmaceuticals Product Portfolio
- 7.5.5 IBA Molecular Imaging Recent Developments
- 7.6 GE Healthcare
- 7.6.1 GE Healthcare Company Information
- 7.6.2 GE Healthcare Business Overview
- 7.6.3 GE Healthcare SPECT Radiopharmaceuticals Revenue and Gross Margin (2021-2026)
- 7.6.4 GE Healthcare SPECT Radiopharmaceuticals Product Portfolio
- 7.6.5 GE Healthcare Recent Developments
- 7.7 Eczacibasi-Monrol
- 7.7.1 Eczacibasi-Monrol Company Information
- 7.7.2 Eczacibasi-Monrol Business Overview
- 7.7.3 Eczacibasi-Monrol SPECT Radiopharmaceuticals Revenue and Gross Margin (2021-2026)
- 7.7.4 Eczacibasi-Monrol SPECT Radiopharmaceuticals Product Portfolio
- 7.7.5 Eczacibasi-Monrol Recent Developments
- 7.8 Curium Pharma
- 7.8.1 Curium Pharma Company Information
- 7.8.2 Curium Pharma Business Overview
- 7.8.3 Curium Pharma SPECT Radiopharmaceuticals Revenue and Gross Margin (2021-2026)
- 7.8.4 Curium Pharma SPECT Radiopharmaceuticals Product Portfolio
- 7.8.5 Curium Pharma Recent Developments
- 7.9 Cardinal Health
- 7.9.1 Cardinal Health Company Information
- 7.9.2 Cardinal Health Business Overview
- 7.9.3 Cardinal Health SPECT Radiopharmaceuticals Revenue and Gross Margin (2021-2026)
- 7.9.4 Cardinal Health SPECT Radiopharmaceuticals Product Portfolio
- 7.9.5 Cardinal Health Recent Developments
- 7.10 Bracco Imaging
- 7.10.1 Bracco Imaging Company Information
- 7.10.2 Bracco Imaging Business Overview
- 7.10.3 Bracco Imaging SPECT Radiopharmaceuticals Revenue and Gross Margin (2021-2026)
- 7.10.4 Bracco Imaging SPECT Radiopharmaceuticals Product Portfolio
- 7.10.5 Bracco Imaging Recent Developments
- 7.11 Bayer (Radiology Division)
- 7.11.1 Bayer (Radiology Division) Company Information
- 7.11.2 Bayer (Radiology Division) Business Overview
- 7.11.3 Bayer (Radiology Division) SPECT Radiopharmaceuticals Revenue and Gross Margin (2021-2026)
- 7.11.4 Bayer (Radiology Division) SPECT Radiopharmaceuticals Product Portfolio
- 7.11.5 Bayer (Radiology Division) Recent Developments
- 7.12 Advanced Accelerator Applications
- 7.12.1 Advanced Accelerator Applications Company Information
- 7.12.2 Advanced Accelerator Applications Business Overview
- 7.12.3 Advanced Accelerator Applications SPECT Radiopharmaceuticals Revenue and Gross Margin (2021-2026)
- 7.12.4 Advanced Accelerator Applications SPECT Radiopharmaceuticals Product Portfolio
- 7.12.5 Advanced Accelerator Applications Recent Developments
8 North America
- 8.1 North America SPECT Radiopharmaceuticals Revenue (2021-2032)
- 8.2 North America SPECT Radiopharmaceuticals Revenue by Type (2021-2032)
- 8.2.1 North America SPECT Radiopharmaceuticals Revenue by Type (2021-2026)
- 8.2.2 North America SPECT Radiopharmaceuticals Revenue by Type (2027-2032)
- 8.3 North America SPECT Radiopharmaceuticals Revenue Share by Type (2021-2032)
- 8.4 North America SPECT Radiopharmaceuticals Revenue by Application (2021-2032)
- 8.4.1 North America SPECT Radiopharmaceuticals Revenue by Application (2021-2026)
- 8.4.2 North America SPECT Radiopharmaceuticals Revenue by Application (2027-2032)
- 8.5 North America SPECT Radiopharmaceuticals Revenue Share by Application (2021-2032)
- 8.6 North America SPECT Radiopharmaceuticals Revenue by Country
- 8.6.1 North America SPECT Radiopharmaceuticals Revenue by Country (2021 VS 2025 VS 2032)
- 8.6.2 North America SPECT Radiopharmaceuticals Revenue by Country (2021-2026)
- 8.6.3 North America SPECT Radiopharmaceuticals Revenue by Country (2027-2032)
- 8.6.4 United States
- 8.6.5 Canada
- 8.6.6 Mexico
9 Europe
- 9.1 Europe SPECT Radiopharmaceuticals Revenue (2021-2032)
- 9.2 Europe SPECT Radiopharmaceuticals Revenue by Type (2021-2032)
- 9.2.1 Europe SPECT Radiopharmaceuticals Revenue by Type (2021-2026)
- 9.2.2 Europe SPECT Radiopharmaceuticals Revenue by Type (2027-2032)
- 9.3 Europe SPECT Radiopharmaceuticals Revenue Share by Type (2021-2032)
- 9.4 Europe SPECT Radiopharmaceuticals Revenue by Application (2021-2032)
- 9.4.1 Europe SPECT Radiopharmaceuticals Revenue by Application (2021-2026)
- 9.4.2 Europe SPECT Radiopharmaceuticals Revenue by Application (2027-2032)
- 9.5 Europe SPECT Radiopharmaceuticals Revenue Share by Application (2021-2032)
- 9.6 Europe SPECT Radiopharmaceuticals Revenue by Country
- 9.6.1 Europe SPECT Radiopharmaceuticals Revenue by Country (2021 VS 2025 VS 2032)
- 9.6.2 Europe SPECT Radiopharmaceuticals Revenue by Country (2021-2026)
- 9.6.3 Europe SPECT Radiopharmaceuticals Revenue by Country (2027-2032)
- 9.6.4 Germany
- 9.6.5 France
- 9.6.6 U.K.
- 9.6.7 Italy
- 9.6.8 Russia
- 9.6.9 Spain
- 9.6.10 Netherlands
- 9.6.11 Switzerland
- 9.6.12 Sweden
- 9.6.13 Poland
10 China
- 10.1 China SPECT Radiopharmaceuticals Revenue (2021-2032)
- 10.2 China SPECT Radiopharmaceuticals Revenue by Type (2021-2032)
- 10.2.1 China SPECT Radiopharmaceuticals Revenue by Type (2021-2026)
- 10.2.2 China SPECT Radiopharmaceuticals Revenue by Type (2027-2032)
- 10.3 China SPECT Radiopharmaceuticals Revenue Share by Type (2021-2032)
- 10.4 China SPECT Radiopharmaceuticals Revenue by Application (2021-2032)
- 10.4.1 China SPECT Radiopharmaceuticals Revenue by Application (2021-2026)
- 10.4.2 China SPECT Radiopharmaceuticals Revenue by Application (2027-2032)
- 10.5 China SPECT Radiopharmaceuticals Revenue Share by Application (2021-2032)
11 Asia (Excluding China)
- 11.1 Asia SPECT Radiopharmaceuticals Revenue (2021-2032)
- 11.2 Asia SPECT Radiopharmaceuticals Revenue by Type (2021-2032)
- 11.2.1 Asia SPECT Radiopharmaceuticals Revenue by Type (2021-2026)
- 11.2.2 Asia SPECT Radiopharmaceuticals Revenue by Type (2027-2032)
- 11.3 Asia SPECT Radiopharmaceuticals Revenue Share by Type (2021-2032)
- 11.4 Asia SPECT Radiopharmaceuticals Revenue by Application (2021-2032)
- 11.4.1 Asia SPECT Radiopharmaceuticals Revenue by Application (2021-2026)
- 11.4.2 Asia SPECT Radiopharmaceuticals Revenue by Application (2027-2032)
- 11.5 Asia SPECT Radiopharmaceuticals Revenue Share by Application (2021-2032)
- 11.6 Asia SPECT Radiopharmaceuticals Revenue by Country
- 11.6.1 Asia SPECT Radiopharmaceuticals Revenue by Country (2021 VS 2025 VS 2032)
- 11.6.2 Asia SPECT Radiopharmaceuticals Revenue by Country (2021-2026)
- 11.6.3 Asia SPECT Radiopharmaceuticals Revenue by Country (2027-2032)
- 11.6.4 Japan
- 11.6.5 South Korea
- 11.6.6 India
- 11.6.7 Australia
- 11.6.8 Taiwan
- 11.6.9 Southeast Asia
12 South America, Middle East and Africa
- 12.1 SAMEA SPECT Radiopharmaceuticals Revenue (2021-2032)
- 12.2 SAMEA SPECT Radiopharmaceuticals Revenue by Type (2021-2032)
- 12.2.1 SAMEA SPECT Radiopharmaceuticals Revenue by Type (2021-2026)
- 12.2.2 SAMEA SPECT Radiopharmaceuticals Revenue by Type (2027-2032)
- 12.3 SAMEA SPECT Radiopharmaceuticals Revenue Share by Type (2021-2032)
- 12.4 SAMEA SPECT Radiopharmaceuticals Revenue by Application (2021-2032)
- 12.4.1 SAMEA SPECT Radiopharmaceuticals Revenue by Application (2021-2026)
- 12.4.2 SAMEA SPECT Radiopharmaceuticals Revenue by Application (2027-2032)
- 12.5 SAMEA SPECT Radiopharmaceuticals Revenue Share by Application (2021-2032)
- 12.6 SAMEA SPECT Radiopharmaceuticals Revenue by Country
- 12.6.1 SAMEA SPECT Radiopharmaceuticals Revenue by Country (2021 VS 2025 VS 2032)
- 12.6.2 SAMEA SPECT Radiopharmaceuticals Revenue by Country (2021-2026)
- 12.6.3 SAMEA SPECT Radiopharmaceuticals Revenue by Country (2027-2032)
- 12.6.4 Brazil
- 12.6.5 Argentina
- 12.6.6 Chile
- 12.6.7 Colombia
- 12.6.8 Peru
- 12.6.9 Saudi Arabia
- 12.6.10 Israel
- 12.6.11 UAE
- 12.6.12 Turkey
- 12.6.13 Iran
- 12.6.14 Egypt
13 Concluding Insights
14 Appendix
- 14.1 Reasons for Doing This Study
- 14.2 Research Methodology
- 14.3 Research Process
- 14.4 Authors List of This Report
- 14.5 Data Source
- 14.5.1 Secondary Sources
- 14.5.2 Primary Sources
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst